Should women receive androgen replacement therapy, and if so, how?
Article first published online: 24 JUL 2009
© 2010 Blackwell Publishing Ltd
Volume 72, Issue 2, pages 149–154, February 2010
How to Cite
Davis, S. R. (2010), Should women receive androgen replacement therapy, and if so, how?. Clinical Endocrinology, 72: 149–154. doi: 10.1111/j.1365-2265.2009.03670.x
- Issue published online: 19 JAN 2010
- Article first published online: 24 JUL 2009
- (Received 25 May 2009; returned for revision 10 June 2009; finally revised 14 June 2009; accepted 16 June 2009)
The available clinical evidence supports efficacy of testosterone therapy for the treatment of postmenopausal women with hypoactive sexual desire disorder (HSDD) who have undergone a comprehensive clinical evaluation. Although few preparations designed to deliver an appropriate dose of testosterone for women are available, use of testosterone by women for the management of HSDD is widespread. Issues that continue to simulate debate in this therapeutic area include whether HSDD is a condition that merits pharmacotherapy, how effective is such treatment and whether testosterone therapy is safe. Hence the question, should women receive androgen replacement therapy, and if so, how?